Last week, Biogen Idec Inc. announced the purchase of Stromedix Inc. to gain access to the start-up's humanized monoclonal antibody, STX-100. The purchase marks a return home for the integrin avb6-targeted drug, which was originally developed by Biogen. (See BioWorld Today, Feb. 15, 2012.)